To examine the anti-leukemia activity of sitravatinib on primary cells, we collected bone marrow cells from 8 patients, 6 of whom were diagnosed as FLT3-ITD and 2 of whom expressed wild-type FLT3. The overall magnitude of antileukemic effect of sitravatinib on blasts harboring FLT3-ITD was more effective than that of quizartinib and gilteritinib regardless of the disease state (Fig. 6A-D). The gene discussed is FLT3; the disease is leukemia.